Skip to content

Zevra Therapeutics, Inc.

ZVRA

CIK 0001434647

← back to feed
Revenue (TTM)
$0
Q1 May 2026
Net Income (TTM)
$108.95M
+178.9% YoY Q1 May 2026
EPS Diluted (TTM)
$1.74
+159.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$22.45M
Q1 May 2026
Cash
$95.6M
Q1 May 2026
Total Debt
$0
Q1 May 2026
Shares Outstanding
59.12M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings